Q3FY18 Results: J B Chemicals posts mixed set of numbers
J B Chemicals reported results for the quarter ended December 31, 2017 on Friday. The company's standalone revenue for the quarter came in at Rs. 304.74 crore, registering 10.2 per cent yoy increase. This was on account of jump in sales from domestic formulations by 13.75 per cent, contrast media by 11.23 per cent, rest of the world exports by 7.16 per cent and Russia exports by 5.22 per cent.
EBITDA for the quarter rose by 28.1 per cent yoy to Rs. 58.61 crore with a corresponding margin expansion of 269 bps. EBITDA margin for the quarter stood at 19.2 per cent. This margin expansion was aided by favourable product mix in domestic formulation business. The PAT for the quarter came in at Rs. 33.85 crore, yoy decline of 5.3 per cent.
During the quarter, USFDA approved company’s supplementary Abbreviated New Drug Application (ANDA) for Atenolol Tablets USP 25 mg, 50 mg and 100mg.
J B Chemicals is one of India’s leading pharmaceutical companies, which manufactures and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs.
On Friday, the stock opened at Rs. 297 and touched an intra-day high and low of Rs. 309.95 and Rs. 296.25, respectively, on the BSE.